— Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters’ option to purchase additional shares —
— Presented continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial being evaluated in patients with r/r MM at the 2022 ASCO Annual Meeting —
— Preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics —
REDWOOD CITY, Calif., Aug. 15, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2022.
“We are excited about the rapid progress we’ve made since becoming a public company in February of this year,” said Rami Elghandour, Arcellx’s Chairman and Chief…
